# Phase 1/2 Scleroderma, Systemic trials recruiting: 20 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 20 trials in phase 1/2 for Scleroderma, Systemic that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1/2 Scleroderma, Systemic trials: 20 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1-2/scleroderma-systemic

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 20
- Recruiting or not yet: 20
- Read on: November 19, 2026

## Trials

The 20 newest of 20, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 18, 2026 | NCT07946367 | Dual-targeting of B & T Cell Pathways Evaluation Trial | Diabetes Free, Inc. | Phase 1/2 | Recruiting | Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc), Idiopathic Inflammatory... | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07946367) |
| November 12, 2026 | NCT07932262 | An Open-label Phase I/II Safety and Feasibility Basket Study of UKT-CART19.1 | University Hospital Tuebingen | Phase 1/2 | Not yet recruiting | Pemphigus Vulgaris (PV), ANCA Associated Vasculitis (AAV), Rheumatoid Arthritis (RA), IIM, Multiple Sclerosis, Immune... | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07932262) |
| September 2, 2026 | NCT07800871 | FT839 in Autoimmune Diseases | Fate Therapeutics | Phase 1/2 | Recruiting | ANCA-Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM), Rheumatoid Arthritis (RA), Systemic Lupus... | 446 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07800871) |
| August 24, 2026 | NCT07782450 | A Study to Learn About a Medicine Called PF-08154225 in Participants With Autoimmune Diseases | Pfizer | Phase 1/2 | Not yet recruiting | Systemic Lupus Erythematosus, Rheumatoid Arthritis, Idiopathic Inflammatory Myositis, Systemic Sclerosis | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07782450) |
| August 21, 2026 | NCT07778446 | A Study to Test CRT-402 in Refractory Autoimmune Disease | Myeloid Therapeutics | Phase 1/2 | Recruiting | Autoimmune Diseases, Systemic Lupus Erythematosus, Systemic Scleroderma, Myositis | 34 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07778446) |
| June 11, 2026 | NCT07641634 | A Phase 1/2 Study of PRO-203 in Healthy Volunteers and Participants With Systemic Sclerosis. | Prolium Bioscience, Inc | Phase 1/2 | Recruiting | Healthy Volunteers, Systemic Sclerosis (SSc), Scleroderma, Systemic, Scleroderma | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07641634) |
| April 17, 2026 | NCT07535931 | Umbilical Cord Mesenchymal Stem Cells (UC-MSC) in the Treatment of Systemic Sclerosis | Shenzhen Huishan Biotechnology Co., Ltd. | Phase 1/2 | Not yet recruiting | Systemic Sclerosis (SSc) | 21 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07535931) |
| March 16, 2026 | NCT07473154 | Controlling Hyperactive Immunity With Long-lived Lymphocytes | Quell Therapeutics Limited | Phase 1/2 | Recruiting | Diffuse Cutaneous Systemic Sclerosis, Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc), Autoimmune Rheumatologic... | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07473154) |
| December 22, 2025 | NCT07295847 | A Study of AZD0120 in Autoimmune Diseases | AstraZeneca | Phase 1/2 | Recruiting | Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07295847) |
| April 27, 2025 | NCT06947473 | Umbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH. | Beijing GoBroad Hospital | Phase 1/2 | Recruiting | Refractory Lupus Nephritis, Systemic Sclerosis, Primary Sjogren&#39;s Syndrome Combined With Pulmonary Hypertension | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06947473) |
| April 27, 2025 | NCT06947460 | CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH | Beijing GoBroad Hospital | Phase 1/2 | Recruiting | Refractory Lupus Nephritis, Systemic Sclerosis, Primary Sjogren&#39;s Syndrome Combined With Pulmonary Hypertension... | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06947460) |
| February 14, 2025 | NCT06828042 | Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases | Peking University Third Hospital | Phase 1/2 | Recruiting | Systemic Lupus Erthematosus, Systemic Sclerosis (SSc), Sjogren Syndrome, ANCA Associated Vasculitis (AAV), Inflammatory... | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06828042) |
| February 12, 2025 | NCT06821659 | Safety and Efficacy of Universal CAR-T Cells (UWD-CD19) Combined With Immunosuppressants in the Treatment of Refractory Autoimmune Diseases | Peking University Third Hospital | Phase 1/2 | Not yet recruiting | Systemic Lupus Erthematosus, Systemic Sclerosis (SSc), Inflammatory Myopathies, ANCA Associated Vasculitis (AAV)... | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06821659) |
| December 13, 2024 | NCT06733935 | A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2) | Nkarta, Inc. | Phase 1/2 | Recruiting | Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Antineutrophil Cytoplasmic Antibody-Associated Vasculitis... | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06733935) |
| December 9, 2024 | NCT06722105 | Phase I/II Randomized Clinical Trial of Allogeneic Adipose Tissue-derived Mesenchymal Stromal Cells Systemic Infusion in Severe Systemic... | Assistance Publique - Hôpitaux de Paris | Phase 1/2 | Not yet recruiting | Severe Systemic Sclerosis | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06722105) |
| May 30, 2024 | NCT06434363 | Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders | M.D. Anderson Cancer Center | Phase 1/2 | Recruiting | Autoimmune Disorders, Systemic Sclerosis, Systemic Lupus Erythematosus, Lupus, Lupus Nephritis | 47 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06434363) |
| April 4, 2024 | NCT06347718 | CAR-T Cells in Systemic B Cell Mediated Autoimmune Disease | Miltenyi Biomedicine GmbH | Phase 1/2 | Recruiting | Systemic Lupus Erythematosus, Systemic Sclerosis, Dermatomyositis, Polymyositis | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06347718) |
| September 28, 2023 | NCT06058091 | RY\_SW01 Cell Injection Therapy in Systemic Sclerosis | Jiangsu Renocell Biotech Company | Phase 1/2 | Recruiting | Systemic Sclerosis | 81 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06058091) |
| April 22, 2020 | NCT04356287 | Treatment With Human Umbilical Cord-derived Mesenchymal Stromal Cells in Systemic Sclerosis | Sponsor not shown (see the record) | Phase 1/2 | Recruiting | Sclerosis, Systemic, Mesenchymal Stem Cells | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04356287) |
| July 7, 2017 | NCT03211793 | Mesenchymal Stromal Cells as Treatment for Digital Ulcers in Systemic Sclerosis | UMC Utrecht | Phase 1/2 | Recruiting | Systemic Sclerosis, Digital Ulcer | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03211793) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Peking University Third Hospital | 2 |
| Beijing GoBroad Hospital | 2 |
| [Miltenyi Biomedicine GmbH](https://specstream.ai/data/clinical-trials/company/miltenyi-biomedicine-gmbh) | 1 |
| University Hospital Tuebingen | 1 |
| [Pfizer](https://specstream.ai/data/clinical-trials/company/pfizer) | 1 |
| UMC Utrecht | 1 |
| Quell Therapeutics Limited | 1 |
| Jiangsu Renocell Biotech Company | 1 |
| [Fate Therapeutics](https://specstream.ai/data/clinical-trials/company/fate-therapeutics) | 1 |
| Nkarta, Inc. | 1 |
| Diabetes Free, Inc. | 1 |
| Myeloid Therapeutics | 1 |
| M.D. Anderson Cancer Center | 1 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 1 |
| Prolium Bioscience, Inc | 1 |
| Assistance Publique - Hôpitaux de Paris | 1 |
| Shenzhen Huishan Biotechnology Co., Ltd. | 1 |

## By country

| Country | Trials |
| --- | --- |
| Germany | 5 |
| China | 5 |
| United States | 4 |
| Australia | 3 |
| Spain | 2 |
| United Kingdom | 2 |
| Canada | 1 |
| Netherlands | 1 |
| Sweden | 1 |
| Mexico | 1 |
| South Korea | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Estate planning law firms in the United States](https://specstream.ai/data/businesses/estate-planning-law-firms/united-states)
- [Ambulance services in the United States](https://specstream.ai/data/businesses/ambulance-services/united-states)
- [Periodontics practices in the United States](https://specstream.ai/data/businesses/periodontics-practices/united-states)
- [Financial services firms in the United States](https://specstream.ai/data/businesses/financial-services-firms/united-states)
- [Auto insurance agencies in the United States](https://specstream.ai/data/businesses/auto-insurance-agencies/united-states)
- [Portuguese restaurants in the United States](https://specstream.ai/data/businesses/portuguese-restaurants/united-states)
